Mrs Kerri-ann Bell, MA CCC/SLP | |
195 Federal Rd, Brookfield, CT 06804-2556 | |
(203) 546-8648 | |
(888) 558-7910 |
Full Name | Mrs Kerri-ann Bell |
---|---|
Gender | Female |
Speciality | Speech-language Pathologist |
Location | 195 Federal Rd, Brookfield, Connecticut |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1255651220 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | 012481-1 (New York) | Secondary |
235Z00000X | Speech-language Pathologist | 003365 (Connecticut) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Kerri-ann Bell, MA CCC/SLP 6 Crystal Ln, New Milford, CT 06776-3957 Ph: (914) 403-7479 | Mrs Kerri-ann Bell, MA CCC/SLP 195 Federal Rd, Brookfield, CT 06804-2556 Ph: (203) 546-8648 |
News Archive
A team of Syracuse University researchers discovered a second molecular switch within the Mixed Lineage Leukemia protein complex that they believe could be exploited to prevent the overproduction of abnormal cells that are found in several types of cancer, including leukemia.
Abcodia today announced that it has raised £5.25 million funding from existing and new investors to bring the world's most sensitive and specific ovarian cancer screening test, ROCA to market.
An innovative study published in the latest online edition of the Journal of Physiology provides the first evidence that the insulin resistance typical of type 2 diabetes can be "programmed" across two generations by poor nutrition during a grandmother's pregnancy and lactation.
Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.
Archimedes Inc., a healthcare modeling and analytics company, today announced results of a simulated clinical trial which found that the seven single-nucleotide polymorphisms (7SNP) genetic test for breast cancer was most cost effective when used to guide MRI screenings for patients found to have an intermediate lifetime risk of developing the disease.
› Verified 2 days ago
Aimee Hannah, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 317 Federal Rd, Brookfield, CT 06804 Phone: 203-740-0582 Fax: 203-740-0618 | |
Mrs. Traci Casey, MS CCC SLP TSHH Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 14 Richards Rd, Brookfield, CT 06804 Phone: 914-589-4655 | |
Ms. Kathleen M. Lord, M.S., CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 246 Federal Rd, Suite D-22, Brookfield, CT 06804 Phone: 203-775-5777 Fax: 203-775-6890 | |
Mrs. Christina B Stauble, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9 Candlewood Hbr, Brookfield, CT 06804 Phone: 203-775-1151 | |
Mrs. Marni Jill Gross, M.S.,CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 12 Pritten Hill Rd, Brookfield, CT 06804 Phone: 203-775-9681 | |
Eliza Shaker, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 11 Arapaho Rd, Brookfield, CT 06804 Phone: 203-885-2405 |